A popular approach to generating tolerogenic DC has been the combination dexamethasone/vitamin D3 conditioning of bone marrow DC (54–57), and these DC were shown to suppress colitis in the CD4+ CD25− colitogenic T-cell transfer SCID model (58). Here, CD4 is linked to colitis.